FTXH News and Press, First Trust Nasdaq Pharmaceuticals ETF From 09/23/20

First Trust Nasdaq Pharmaceuticals ETF (FTXH) declares $0.0428/share quarterly dividend, -7.6% decrease from prior dividend of $0.0463.Forward yield 0.73%Payable Sept. 30; for shareholders of record Sept. 25; ex-div Sept. 24.See FTXH Dividend Scorecard, Yield Chart, & Dividend Growth. F...

By Ansh Chaudhary The ETF Deathwatch decreased in size in May. Sixteen exchange-traded products ("ETPs") were added to the list, and 32 funds were removed. Twenty-one of those funds were removed due to increased health and 11 were due to asset managers closing their funds. That so many fun...

On April 23rd 2020, LLY held its Q1 2020 call. We dissect main points and summarize key takeaways for investors. Company comments cited below are from the conference call transcript . Q1 Company Results LLY outperformed in Q1 2020. The company posted Q1 non-GAAP EPS of $1.75 per share (...

By Vinay Thapar and Frank Caruso US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. But investors can find good opportunities in the sector in companies with strong long-term business drivers that are relatively immune to ...

By Michelle Borré, CFA, Head of Fundamental Alternative Strategies , and Brian Giesen, CFA, Intermediate Research Analyst Restrictions on the pricing of drugs delivered in doctors' offices and hospitals could have significant investment implications. The Trump Administration is...

It's time to talk about a new venture called EQRx. This has made quite a splash in the last few days at the JPMorgan investor conference, and it's been launched by Alexis Borisy (involved with founding and/or helping run CombinatoRx, Foundation, Blueprint, WarpDrive Bio, Editas, Relay, and oth...

Success is not final; failure is not fatal: it is the courage to continue that counts. - Winston Churchill Not all companies are scared of a drug losing patent protection. Generics are drugs identical in chemical composition to the original medicines, and hence, rely heavily on the e...

Look to the nervous system as the key to maximum health. - Galen The US is the largest manufacturer and consumer of pharmaceuticals and spends the most on research & development. The most logical result follows. American companies are fetching the most revenues from around the worl...

By Stephen H. Dover, CFA, Executive Vice President, Head of Equities, Krzysztof Musialik, CFA, Research Analyst, Franklin Templeton Emerging Markets Equity, and Steve Kornfeld, CFA, Portfolio Manager, Research Analyst, Franklin Equity Group The biopharma industry has the potential to save...

By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But U.S. drug reform is far from over, with implica...